Is CYTK or DARE more undervalued in 2026?

CirclFi compares Cytokinetics, Incorporated (CYTK) and Dare Bioscience, Inc. (DARE) using 13 institutional-grade valuation models. CYTK has a Quality of Company score of 5.9/10 while DARE scores 4.4/10.

Which is a better buy — CYTK or DARE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CYTK and DARE valuations compare?

CYTK at $76.81 and DARE at $2.28 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CYTK vs DARE Valuation Comparison 2026 — Intrinsic Value Analysis

CYTK

Biotechnology

Cytokinetics, Incorporated

Quality

5.9

out of 10

Value Trap

LOW

Price

$76.81

Last close

Models

9/13

Active

DARE

Biotechnology

Dare Bioscience, Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$2.28

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CYTK Fair Value	CYTK Upside	DARE Fair Value	DARE Upside
Bayesian DCF	Intrinsic	$24.22	-68.5%	$1.22	-46.5%
Earnings Power Value	Intrinsic	$21.45	-67.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$2.81	+23.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CYTK vs DARE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CYTK vs DARE — Which Stock Is More Undervalued?

CYTK scores higher with a 5.9/10 quality rating vs DARE's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cytokinetics, Incorporated (CYTK) and Dare Bioscience, Inc. (DARE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CYTK currently trades at $76.81 with a QOC of 5.9/10, while DARE trades at $2.28 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).